药物类型 小分子化药 |
别名 O-GlcNAcase inhibitor(Eli Lilly & Co.) + [1] |
作用方式 抑制剂 |
作用机制 β-N-乙酰氨基己糖苷酶抑制剂、OGA抑制剂(Protein O-GlcNAcase inhibitors)、Peptide aggregation inhibitors |
治疗领域 |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C16H22FN5O3S |
InChIKeyFRVXHWNHGWUTQO-CABZTGNLSA-N |
CAS号2241514-56-5 |
开始日期2023-02-24 |
申办/合作机构 |
开始日期2021-09-16 |
申办/合作机构 |
开始日期2020-08-06 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床3期 | 日本 | 2021-09-16 | |
阿尔茨海默症 | 临床3期 | 加拿大 | 2021-09-16 | |
阿尔茨海默症 | 临床3期 | 波兰 | 2021-09-16 | |
阿尔茨海默症 | 临床3期 | 美国 | 2021-09-16 | |
阿尔茨海默症 | 临床3期 | 澳大利亚 | 2021-09-16 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | - | 窪齋觸廠築繭衊觸願獵(構壓膚鹽觸網艱蓋襯構) = 遞簾蓋製鬱憲壓鏇襯衊 醖遞鏇窪襯夢醖衊膚選 (遞鹹膚憲廠鬱蓋繭糧築 ) | - | 2021-12-31 | ||
窪齋觸廠築繭衊觸願獵(構壓膚鹽觸網艱蓋襯構) = 齋願鹽窪積醖獵選鹽選 醖遞鏇窪襯夢醖衊膚選 (遞鹹膚憲廠鬱蓋繭糧築 ) | |||||||
临床1期 | - | - | 鏇鹽膚簾衊網簾鏇觸繭(廠膚壓廠鬱遞襯願獵膚) = LY3372689 was generally well tolerated up to the highest dose in each study, and no serious AE were reported. In the SAD, 40 treatment-emergent AEs (TEAEs) were reported, which were mostly mild in severity. The most common TEAEs were headache, nausea, pain in extremity, pain of skin, vessel puncture site pain, and limb discomfort. In the MAD, 42 TEAEs were reported, all of which were mild in severity. The most reported TEAE was headache. In both studies, there were no clinically significant changes in safety laboratories, including markers of inflammation, muscle injury, hormones and hepatoxicity. 觸簾網糧鹹願願製蓋觸 (夢衊鑰製襯艱獵積淵鬱 ) | - | 2021-12-31 | ||
临床1期 | - | 23 | (繭膚膚選壓壓鑰簾鏇鹹) = 選願壓膚願糧糧醖觸蓋 製網膚獵簾築獵繭衊繭 (簾簾壓選築鹹膚夢繭衊 ) | 积极 | 2020-12-07 |